UCMD dermatitis

UCMD stands for immunosuppression. UCMD dermatitis (skin inflammation caused by addiction to topical immunosuppressants; UCMD is from the Vietnamese "ức chế miễn dịch") develops when a person with an addiction-prone constitution uses a UCMD substance such as a corticosteroid, tacrolimus, pimecrolimus or cyclosporine. The disease begins when the substance is used, and withdrawal is one phase in its course. The names below differ in scope.

Related terms

Viêm da nghiện UCMD / Bệnh viêm da do nghiện UCMD / UCMD dermatitis: Other names for “UCMD dermatitis — skin inflammation caused by addiction to topical immunosuppressants (UCMD, from the Vietnamese 'ức chế miễn dịch')” in the Frigate knowledge system.
Mixed-cream addiction: A folk term. It is accurate when the addictive substance is in mixed creams. It does not cover cases involving prescription drugs or tacrolimus.
Corticosteroid-damaged skin: A term that describes the consequence. It does not describe the mechanism, and it does not tell apart people who are predisposed to addiction from people who are not.
Corticosteroid-addicted skin: The closest in meaning of the folk terms. It is narrower than UCMD-addicted skin, though, because it leaves out the other immunosuppressants.
TSA — Topical Steroid Addiction: A special case of UCMD dermatitis, when the addictive substance is a topical corticosteroid.
TSW — Topical Steroid Withdrawal: The withdrawal phase when the substance is a topical corticosteroid. It is a phase in the course of the disease, not the name of the whole disease.
TSR — Topical Steroid Resistance: Topical corticosteroids stop working. This is drug resistance, which is different from addiction.
RSS — red skin syndrome (red-skin flare): A type of flare during the course of UCMD, with widespread redness and burning. It is not used as another name for the whole disease.

Basis of this section: Dr. Mototsugu Fukaya's writings on topical steroid addiction.

Understanding UCMD dermatitis correctly

What is UCMD?

UCMD is short for the Vietnamese "ức chế miễn dịch", meaning immunosuppressants. The group includes corticosteroids, tacrolimus, pimecrolimus and cyclosporine. UCMD dermatitis (skin inflammation caused by addiction to topical immunosuppressants) is a dermatitis that arises when a person with an addiction-prone constitution uses these substances. It is the central issue of Frigate's body of knowledge on UCMD.

The disease occurs only in people with a susceptible constitution, estimated at about 15% of the population. This constitution is already present before any exposure to the substance. Whenever someone in this group uses a UCMD substance, the disease arises. People without this constitution can still have the usual side effects of corticosteroids, but that is a separate issue from addiction.

Two phases to tell apart

While the person is using a UCMD substance, the skin may look fine because it is suppressed, but the disease keeps progressing underneath. Don't take the skin's appearance during this phase as proof that it has recovered.
When the person stops the UCMD substance, the skin enters its most severe flare phase. Stopping the substance does not cause the disease. Withdrawal is one phase of a disease that began when the substance was first used.

What changes how a case is read When skin flares after a UCMD substance is stopped, place the flare within the course of the whole case. Don't immediately put it down to withdrawal. The point when the disease began and the point when withdrawal began are two different points.

Four flare patterns

Red-skin flare, also called RSS (red skin syndrome): redness that spreads widely, with burning.
Oozing flare: serous fluid seeps continuously from the inflamed areas.
Dry, peeling flare: the skin becomes dry and sheds scales in large patches.
Inflammatory acne flare: inflamed pimples appear densely. A single case can shift between several patterns over the same journey.

Common terms

TSA (Topical Steroid Addiction): a special case of UCMD dermatitis in which the addictive substance is a corticosteroid.
TSW (Topical Steroid Withdrawal): a special case of UCMD withdrawal in which the substance is a corticosteroid.
TSR (topical steroid resistance): the medication stops working, which is different from addiction.
"Mixed-cream addiction" covers only cases where the UCMD substance is in mixed creams. The term leaves out people who use prescription medications or tacrolimus.

The starting point for management

The four-action protocol, the recovery roadmap and the spa protocol all refer back to this definition. When you take on a case, read the section on tracking progress next. It explains how to understand reactions after an intervention and trends across multiple episodes.

Basis of this section: Frigate's own framework, built from its work with clients who have UCMD dermatitis.

Reading UCMD Skin Along Its Course

A single symptom sits on a whole path

UCMD-addicted skin (UCMD: ức chế miễn dịch, immunosuppression) must be read along the path of its course. Increased redness, burning or pustules right after an intervention are not enough to conclude where the whole case is heading. The immune system is reorganising; an intervention may make symptoms worse in the short term and then bring the skin to a more stable state.

Five pieces of data the record must contain

Record the date the intervention was performed or the product was started.
Record the baseline before the intervention: what state the skin is in, and in which areas.
Record what happened after the intervention and how long the reaction lasted.
Record the state when the reaction ends, compared with the original baseline.
Compare the trend across multiple episodes: are later episodes milder or more severe, do they end sooner or last longer.

Situations that already have a reading in the Frigate professional knowledge base

Pustules appearing on skin that was previously only red: this is a good progression when the redness decreases or stabilises at the same time, the pus stays localised and does not spread quickly, and there is no prolonged high fever. The source's reading is that the immune system is beginning to kill bacteria and push the pus out.
After leukocyte-rich Meso PRP, i.e. injecting platelet- and leukocyte-rich plasma into the skin: a stronger flare lasting about four days is an expected reaction when the episode then ends, the skin stabilises and is better than baseline, and later episodes are milder.
Burning during numbing-cream application on skin that is in a flare: go on to read how long the reaction lasts, how it ends, and the overall state after the session. In this situation the source of irritation is known: the anaesthetic, with short contact.
LFS 20 kHz ultrasound, i.e. low-frequency ultrasound, before applying HA 100k Da (Hyaluronic Acid with a molecular weight of 100,000 Daltons): the source records faster recovery after the session when the skin tolerates the coupling gel and there are no large open wounds.

Keep the conditions attached to the conclusion Each reading above comes with specific conditions. Do not separate a sign such as pustules or a flare from the state of the redness, how far it spreads, fever, and the end point of the episode, and then apply it to every case.

Situations without a confirmed reading pattern

Increased oozing, increased itching, widely spreading redness, heavier dryness and peeling, localised swelling, and reactions after certain light-based techniques are on the list with no SBU data confirming a reading. For these situations, record the sequence of events clearly and take the case into the reaction-pattern identification step with the professional lead, instead of filling in a conclusion borrowed from another situation.

Signals that need immediate action within the course-reading framework

A clear allergic reaction with swelling, blisters, or spread to areas where nothing was applied is a signal to stop immediately.
Severe infection, prolonged high fever, serious dehydration, or pain that keeps increasing with no sign of easing over several days needs emergency care; do not wait for the reaction path to finish.

How to read at the next appointment

Use the same photo set and the five pieces of data in the record to answer three questions: how long this episode lasted, where the skin ended up after the episode compared with before the session, and which direction the next episode is going. This is the basis for assessing response along the course.

Basis of this section: Frigate's own framework, built from its work with clients who have UCMD dermatitis.

UCMD recovery roadmap and milestones for introducing actives

Reading the timeline alongside the skin's condition

The recovery roadmap has three phases: the initial flare, the diminishing flares, and the phase of durable skin barrier regeneration. The timeline milestones are an orienting map; the criteria for progress lie in the trend across multiple flares and in the skin's actual condition.

Short term: from day one to about three months

The first flare after stopping UCMD (immunosuppressants) completely is usually the most severe and the longest. Two things start immediately: taking periodic photos and using HA 100k Da, i.e. Hyaluronic Acid with a molecular weight of 100.000 Dalton; this active can be used even while the skin is flaring.

Medium term: about three to twelve or eighteen months

Good progress shows up as decreases on three dimensions together: flare intensity, the duration of each flare, and how often flares occur. Compare the trend across three to four flares instead of comparing just one flare with the one right before it. When good-skin windows take up more than half of the time, the case has reached a clear recovery threshold.

Milestones worth noting include sleeping five to six hours straight without being woken by itching, the skin drying and scabbing on its own, and areas of good skin appearing and then expanding.
Being able to return to work or go out again, lymph nodes becoming less swollen during mild flares, and burning decreasing even though redness remains are also progress milestones.
One or two unusually severe flares do not change the overall trend. When such a flare occurs, review allergenic foods, major stress, opportunistic infections, product changes, and weather changes.

The phase that seems to stand still Around months four to eight, the person may feel they are neither moving forward nor back. The source describes the immune system as restructuring at a deep level; periodic photos may show improvement even when the subjective sense does not yet register it. This is the phase in which keeping up a support community is needed.

Long term: about twelve to thirty-six months

Recovering from UCMD addiction means that flares driven by the addiction mechanism no longer occur. An underlying skin condition such as atopic dermatitis or rosacea, a chronic red-skin condition, may still remain and continue to be managed with non-UCMD methods.

No flares from stopping UCMD for at least three to six consecutive months.
The skin responds normally to the environment, sleep is normal, and there is no night-time itching.
Exposure to minor triggers does not cause a whole-body flare.

The three-step order of actives

HA 100k Da starts right from the beginning and is continued through the later phases. The goal stated in the source is to activate CD44, a cell receptor, to promote epidermal cell proliferation. HAIM Serum is the Frigate product containing HA 100k Dalton (Hyaluronic Acid with a molecular weight of 100.000 Dalton).
Niacinamide, i.e. vitamin B3, starts after the skin has been stable for three to four consecutive weeks, usually around months six to nine. The source places this step after HA to reinforce ceramides, reduce post-inflammatory marks, and regulate sebum.
Retinol, a form of vitamin A, starts only once fully recovered with no flares for at least three consecutive months, usually from months twelve to eighteen. The source gives a starting level of 0.025% to 0.1%; this is the active-ingredient milestone of the roadmap.

How to use the twenty percent rule

Fukaya used the clinical impression that TSW (Topical Steroid Withdrawal) lasts approximately 20% of the time topical corticosteroids were used, to set a rough initial expectation. For example, ten years of use corresponds to about two years of recovery. The source specifies that this figure should not be used to assess progress; assessment still relies on photos and the clinical course.

Basis of this section: Frigate's own framework, built from its work with clients who have UCMD dermatitis; Barnes 2012 (J Invest Dermatol); Dr. Mototsugu Fukaya's writings on topical steroid addiction.

Thin, weak, sensitive skin: restore the barrier first

The skin barrier and water retention

TEWL, Transepidermal Water Loss, is the amount of water lost through the epidermis into the environment. The source treats rising TEWL as a sign of a damaged barrier, and TEWL falling back to normal as a sign of barrier recovery. Water escapes when the bonds between corneocytes are broken, when the lipid layers between cells are depleted, or when cells lack natural moisturizing factors.

Filaggrin is a structural protein that helps build a strong stratum corneum. It then breaks down into NMF, Natural Moisturizing Factor, the skin's own natural humectants. To read thin, weak skin, you need to look at two things: how the barrier is built and how well the cells hold water.

Two approaches recorded in the Frigate professional knowledge base

The Frigate professional knowledge base, under Thin, weak, sensitive skin, uses colloidal silver to prevent secondary infection, where microorganisms cause further inflammation on skin that is already weakened. HA 100k Da, meaning Hyaluronic Acid with a molecular weight of 100,000 Daltons, is the approach for thickening thin, atrophied skin.

HAIM for thickening the skin

HAIM serum contains HA 100k Dalton (Hyaluronic Acid with a molecular weight of 100,000 Daltons) and Nano Silver. The product page states that it thickens thin, weak, sensitive skin in three months and restores corticosteroid-induced skin atrophy in three to six months. The directions say to apply the serum after toner and before moisturizer.

Gen2 for recovery and soothing

Gen2 toner contains Copper Tripeptide-1, a copper complex with a chain of three amino acids, and vitamin B5. The product page presents Gen2 as an option for thickening thin, weak skin and reducing irritation, as strong as HAIM, that also soothes the skin when strong skincare actives are in use.

Lowering the load when introducing a product

On weak skin, discomfort depends on the amount, the area covered, contact time, frequency, and whether the skin is flaring or calm. The same product can sting during a flare but be usable once the skin is calmer. Assess the current load instead of only asking whether a product suits the skin.

The first time, leave the product on for five to fifteen minutes and then rinse it off. Increase the time gradually as the skin tolerates it.
Start every other day, or once every two to three days, and pick days when the skin is calmer.
Apply a very thin layer to a small area, and introduce only one new product at a time.
Wait until the skin returns to baseline, then do a second test at a lower load to compare the trend.

If the underlying skin has UCMD addiction

UCMD refers to the group of immunosuppressants. The recovery roadmap uses HA 100k Da right from the start, even during flares. It adds Niacinamide (vitamin B3) after three to four weeks of stability, and Retinol (a form of vitamin A) once the skin has fully healed and gone at least three months without a flare. Keep to these milestones when choosing how to restore weak skin.

The trend decides how you continue If discomfort is milder and shorter the next time, the skin is adapting. If reactions get progressively worse, or you see fast-spreading redness, swelling, blisters, or spread to areas where the product was not applied, stop the product and reassess.

Published literature on topical steroid addiction and withdrawal

Fukaya M, Sato K, Sato M, et al. Topical steroid addiction in atopic dermatitis. Drug, Healthcare and Patient Safety, 2014. PMID 25378953.
Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. Journal of the American Academy of Dermatology, 2015. PMID 25592622.